CYP2D6 genotype predicts tamoxifen discontinuation and drug response: a secondary analysis of the KARISMA trial.
Saved in:
| Title: | CYP2D6 genotype predicts tamoxifen discontinuation and drug response: a secondary analysis of the KARISMA trial. |
|---|---|
| Authors: | He, W.1,2,3, Eriksson, M.3, Eliasson, E.4, Grassmann, F.3,5, Bäcklund, M.3, Gabrielson, M.3, Hammarström, M.3, Margolin, S.6,7, Thorén, L.6,7, Wengström, Y.8, Borgquist, S.9,10, Hall, P.1,3,6 per.hall@ki.se, Czene, K.3 |
| Source: | Annals of Oncology. Oct2021, Vol. 32 Issue 10, p1286-1293. 8p. |
| Database: | Academic Search Ultimate |
| ISSN: | 09237534 |
|---|---|
| DOI: | 10.1016/j.annonc.2021.07.005 |
